No, Eliquis Should Not Be Prescribed
A 70-year-old patient with diabetes, hypertension, and hyperlipidemia but without atrial fibrillation should NOT be given Eliquis (apixaban). Anticoagulation with apixaban is specifically indicated for stroke prevention in patients with atrial fibrillation, not for primary prevention in patients with cardiovascular risk factors alone 1.
Why Anticoagulation Is Not Indicated
The evidence is unequivocal: anticoagulants like apixaban are only recommended for patients who have atrial fibrillation (or other specific indications like venous thromboembolism or mechanical heart valves). The FDA labeling for Eliquis clearly states its approved indication is "reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation" 1.
All major guidelines from the AHA/ACC/HRS 2 and ESC 3 consistently emphasize that:
- Anticoagulation decisions are based on the presence of atrial fibrillation combined with stroke risk stratification using CHA₂DS₂-VASc scoring
- The presence of diabetes, hypertension, and age alone—without atrial fibrillation—does not warrant anticoagulation
Understanding the Risk Stratification Context
The patient's risk factors (diabetes, hypertension, age 70) would contribute to a CHA₂DS₂-VASc score calculation only if atrial fibrillation were present. The CHA₂DS₂-VASc score was specifically developed and validated for patients with atrial fibrillation to assess their stroke risk from cardioembolic sources 4, 5, 2.
Without atrial fibrillation, this patient's stroke risk stems from atherosclerotic disease, not cardioembolic mechanisms. For atherosclerotic stroke prevention, the appropriate interventions are:
- Aggressive blood pressure control
- Statin therapy for hyperlipidemia
- Glycemic control for diabetes
- Antiplatelet therapy (aspirin or clopidogrel) if indicated based on cardiovascular risk assessment
- Lifestyle modifications
The Harm of Inappropriate Anticoagulation
Prescribing apixaban to this patient would expose them to:
- Significant bleeding risk without any proven benefit for stroke prevention in the absence of atrial fibrillation
- Major bleeding rates of approximately 2-3% per year based on trial data 1
- Intracranial hemorrhage risk
- Gastrointestinal bleeding risk
- Unnecessary medication cost and complexity
The pivotal ARISTOTLE trial that established apixaban's efficacy specifically enrolled patients with documented atrial fibrillation 1. There is no evidence supporting anticoagulation for primary stroke prevention in patients with cardiovascular risk factors but no atrial fibrillation.
Critical Clinical Pitfall to Avoid
Do not confuse stroke risk factors with indications for anticoagulation. While diabetes, hypertension, and age are components of the CHA₂DS₂-VASc score, this scoring system only applies to patients who already have atrial fibrillation. The score helps determine which AF patients need anticoagulation—it does not identify patients who need screening for AF or who should receive empiric anticoagulation.
What Should Be Done Instead
For this 70-year-old patient with diabetes, hypertension, and hyperlipidemia:
- Screen for atrial fibrillation if not recently done, especially given age and cardiovascular risk factors
- Optimize cardiovascular risk factor management:
- Target blood pressure <130/80 mmHg
- Statin therapy for LDL-C reduction
- Hemoglobin A1c control
- Consider antiplatelet therapy (low-dose aspirin 81 mg daily) only if there is established atherosclerotic cardiovascular disease or very high 10-year ASCVD risk
- If atrial fibrillation is subsequently detected, then reassess for anticoagulation using CHA₂DS₂-VASc scoring
The patient would have a CHA₂DS₂-VASc score of 3 (1 point each for hypertension, diabetes, and age 65-74 years) if AF were present, which would make anticoagulation with apixaban appropriate at that time 2.